| WB | 1/300 - 1/800 | Human,Monkey |
| IF | 咨询技术 | Human,Monkey |
| IHC | 咨询技术 | Human,Monkey |
| ICC | 技术咨询 | Human,Monkey |
| FCM | 咨询技术 | Human,Monkey |
| Elisa | 1/10000 | Human,Monkey |
| Aliases | mu2; AP50; CLAPM1 |
| Entrez GeneID | 1173 |
| clone | 4F1B2 |
| WB Predicted band size | 49.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Monkey |
| Immunogen | Purified recombinant fragment of human AP2M1 (AA: 298-435) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于AP2M1抗体的3篇参考文献示例(内容基于典型研究场景，具体文献需核实)：
---
1. **文献名称**：**"AP2M1 regulates amyloid-β protein precursor trafficking and processing"**
**作者**：Zhao et al.
**摘要**：研究AP2M1在阿尔茨海默病中的作用，通过特异性抗体证实AP2M1与APP的相互作用，调控其内吞和淀粉样蛋白生成。
---
2. **文献名称**：**"A novel AP2M1 mutation associated with intellectual disability alters endosomal trafficking"**
**作者**：Wang et al.
**摘要**：报道AP2M1基因突变导致智力障碍的机制，利用Western blot和免疫荧光(基于AP2M1抗体)揭示突变对细胞内吞途径的影响。
---
3. **文献名称**：**"Clathrin adaptor AP2M1 controls EGFR signaling by regulating receptor internalization"**
**作者**：Chen et al.
**摘要**：通过AP2M1抗体阻断实验，证明AP2M1在EGFR内吞中的关键作用，影响癌细胞信号通路及增殖。
---
**注意**：以上为示例，实际文献需通过数据库(如PubMed、Google Scholar)检索确认。建议使用关键词“AP2M1 antibody”或“AP2M1 function”查找最新研究。
The AP2M1 antibody is a crucial tool in studying the adaptor protein complex 2 mu subunit (AP2M1), a key component of the heterotetrameric AP-2 complex involved in clathrin-mediated endocytosis (CME). AP2M1 facilitates the internalization of transmembrane receptors, cargo proteins, and lipids by linking clathrin to vesicle membranes and recognizing specific sorting signals like tyrosine-based motifs. This antibody helps researchers detect AP2M1 expression levels, monitor its subcellular localization, and explore its role in membrane trafficking pathways.
Dysregulation of AP2M1 is associated with neurodevelopmental disorders, cancer progression, and neurological conditions such as Alzheimer’s disease, where impaired CME contributes to amyloid-beta pathology. Studies also link AP2M1 mutations to rare genetic diseases like MEDNIK syndrome and hereditary spastic paraplegia. By enabling immunoassays (e.g., Western blot, immunofluorescence), the antibody supports investigations into AP2M1’s interaction partners, post-translational modifications, and functional alterations in disease models. Its specificity and reliability make it essential for dissecting molecular mechanisms of endocytosis and developing therapeutic strategies targeting membrane trafficking defects.
×
